Author:
Routman David M.,Chera Bhishamjit S.,Gupta Gaorav P.
Publisher
Ovid Technologies (Wolters Kluwer Health)
Reference59 articles.
1. Trastuzumab deruxtecan in previously treated HER2-positive breast cancer;N Engl J Med,2019
2. Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer;N Engl J Med,2019
3. Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy;Science,2018
4. Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial;Lancet Oncol,2018
5. Tumor mutational load predicts survival after immunotherapy across multiple cancer types;Nat Genet,2019
Cited by
20 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献